Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059-Reference-Cited by-同舟云学术

Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Published:2017-05-18 Issue:20 Volume:129 Page:2808-2810
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Walter Harriet S.¹^ORCID,Jayne Sandrine¹^ORCID,Rule Simon A.²^ORCID,Cartron Guillaume³,Morschhauser Franck⁴⁵^ORCID,Macip Salvador¹^ORCID,Karlin Lionel⁶,Jones Ceri⁷,Herbaux Charles⁴⁵,Quittet Philippe³,Shah Nimish²,Hutchinson Claire V.¹²,Fegan Christopher⁷^ORCID,Yang Yingsi⁸,Mitra Siddhartha⁸,Salles Gilles⁶^ORCID,Dyer Martin J. S.¹^ORCID

Affiliation:

1. Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom;

2. Department of Clinical Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom;

3. Department of Clinical Hematology and Unité Mixte de Recherche–Centre National de la Recherche Scientifique 5235, Centre Hospitalier Régional Universitaire, Montpellier, France;

4. EA 7365 Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University of Lille, Lille, France;

5. Department of Hematology, Centre Hospitalier Régional Universitaire, Lille, France;

6. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hématologie, Pierre-Bénite, Université Claude Bernard Lyon 1, Lyon, France;

7. Cardiff Chronic Lymphocytic Leukemia Research Group, School of Medicine, Cardiff University, Cardiff, United Kingdom; and

8. Gilead Sciences, Inc, Foster City, CA

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/20/2808/1400471/blood765115.pdf

Reference19 articles.

1. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia;Maddocks;Semin Oncol,2016

2. B cell receptor inhibition as a target for CLL therapy;Jeyakumar;Best Pract Res Clin Haematol,2016

3. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2013

4. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;J Clin Oncol,2013

5. Ibrutinib in B lymphoid malignancies;Smith;Expert Opin Pharmacother,2015

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances;Leukemia & Lymphoma;2024-04-10

2. New Means and Challenges in the Targeting of BTK;Clinical Cancer Research;2024-04-05

3. B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia;Frontiers in Oncology;2024-02-26

4. A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications;Molecules;2023-12-11

5. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-10